Arena Pharma (ARNA) KOL Call and Data Are Encouraging - Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
H.C. Wainwright Has Increased Confidence in Arena Pharma (ARNA) AD Program After KOL Event
September 30, 2021 9:00 AM EDTH.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $120.00 price target on Arena Pharma (NASDAQ: ARNA) after a KOL event highlights etrasimod potential in atopic dermatitis.
The analyst commented, "Earlier this week, Arena hosted a KOL event highlighting the potential for lead compound etrasimod, a next-generation S1P modulator, to demonstrate favorable safety, tolerability, and efficacy in moderate-to-severe atopic dermatitis (AD) patients. Highlights: (1) the KOL emphasized the need for a mechanism with... More
